Omega Pharma Makes First Acquisition of Inpha

Omega Pharma, under the guidance of 21 Invest, has successfully completed its first major acquisition by taking over Inpha 2000, an Italian firm specializing in the research, development, and commercialization of scientifically backed nutraceuticals. This strategic move marks an important step in Omega Pharma's plan to consolidate its position as a leader in the Italian dietary supplements market and eventually expand its footprint across Europe. Omega Pharma, established in 1995, is known for its innovative and high-quality products in various therapeutic areas. With the acquisition of Inpha, which focuses on complementary therapeutic sectors like cardiology and neurology, Omega Pharma is set to achieve significant cross-selling synergies, expanding its national reach and product range. The acquisition reflects a shared business model and sales strategy, centered around delivering medical-scientific information exclusively to specialist and general practitioners. Founders of Inpha, Giuseppe Samaritani and Simone Castelli, will remain shareholders and participate in the group's capital, while current CEO, Marco Pratesi, will continue to lead Inpha, ensuring managerial continuity. The collaboration is poised to create a market-leading entity aiming to surpass €30 million in revenues by 2025, leveraging a network of 150 national representatives and expanding sales through pharmacies and digital channels. Notably, 21 Invest, founded by Alessandro Benetton, sees this acquisition as a pivotal move in building a dominant player in the dynamic nutraceutical market in Italy and beyond, a vision shared by both Omega Pharma and Inpha's leadership teams.